Clinical trial
Effectiveness and Safety for Re-treatment With Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) CD30+ Malignancies: a Retrospective Medical Chart Review Study in Spain
NCT04998331 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness and Safety for Re-treatment With Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) CD30+ Malignancies: a Retrospective Medical Chart Review Study in Spain
- Lead sponsor
- Takeda
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 29, 2021
- Completion date
- September 7, 2023
- Enrollment
- 51 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.